evaxion-biotech-logo1big.png
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 22, 2022 06:30 ET | Evaxion Biotech
Completed follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) raising net proceeds of $24.9 million after deducting underwriting discounts,...
evaxion-biotech-logo1big.png
Evaxion Biotech Strengthens Management Team with Two Senior Appointments
March 14, 2022 07:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies...
evaxion-biotech-logo1big.png
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
March 07, 2022 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
January 26, 2022 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
January 18, 2022 08:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
November 09, 2021 17:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
November 09, 2021 06:30 ET | Evaxion Biotech
Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
November 05, 2021 06:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital
October 26, 2021 07:49 ET | Evaxion Biotech
COPENHAGEN, Denmark, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
October 25, 2021 05:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...